Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINC1 | P01008 | 3/20 | 0.40 |
| ▸ | FGF1 | P05230 | 4/20 | 0.39 |
| ▸ | HPSE | Q9Y251 | 6/20 | 0.36 |
| ▸ | FGF2 | P09038 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 5/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12552013 | 0.94 | SERPINC1 (0.39) | SERPINC1FGF1HPSEFGF2F10 | |
| SCHEMBL15127138 | 0.94 | SERPINC1 (0.39) | SERPINC1FGF1HPSEFGF2F10 | |
| SCHEMBL12552044 | 0.93 | SERPINC1 (0.39) | SERPINC1FGF1HPSEFGF2F10 | |
| SCHEMBL14039158 | 0.89 | SERPINC1 (0.35) | SERPINC1FGF1HPSEFGF2F10 | |
| SCHEMBL15127151 | 0.85 | FGF1 (0.36) | SERPINC1FGF1HPSEFGF2F10 | |
| SCHEMBL12551994 | 0.85 | SERPINC1 (0.38) | SERPINC1FGF1HPSEFGF2F10 | |
| SCHEMBL14039089 | 0.85 | SERPINC1 (0.38) | SERPINC1FGF1HPSEFGF2F10 | |
| SCHEMBL18539806 | 0.82 | FGF1 (0.50) | SERPINC1FGF1HPSEFGF2F10 | |
| SCHEMBL18826197 | 0.80 | FGF1 (0.54) | SERPINC1FGF1HPSEFGF2F10 | |
| SCHEMBL12551998 | 0.79 | SERPINC1 (0.34) | SERPINC1FGF1FGF2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318696-B2 | Polysaccharides with antithrombotic activity comprising at least one covalent bond with biotin or a biotin derivative | SANOFI (FR) | 2012-11-27 | — | — | US | disclosed |
| US-20110144042-A1 | Novel Polysaccharides with Antithrombotic Activity Comprising at Least One Covalent Bond with Biotin or a Biotin Derivative | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144042-A1 | Novel Polysaccharides with Antithrombotic Activity Comprising at Least One Covalent Bond with Biotin or a Biotin Derivative | SERPINC1, SELP, FGB | SERPINC1 1/4885FGF1 3910/4885HPSE 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.